Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
Immunotherapy, represented by immune checkpoint inhibitors (ICI), is transforming the treatment of cancer. However, only a small percentage of patients show response to ICI, and there is an unmet need for biomarkers that will identify patients who are more likely to respond to immunotherapy. The fun...
Main Authors: | Shixiang Wang, Zaoke He, Xuan Wang, Huimin Li, Xue-Song Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2019-11-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/49020 |
Similar Items
-
An antigen processing and presentation signature for prognostic evaluation and immunotherapy selection in advanced gastric cancer
by: Ke-wei Wang, et al.
Published: (2022-10-01) -
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
by: Shixiang Wang, et al.
Published: (2019-09-01) -
Identification of tumor antigens and immunogenic cell death-related subtypes for the improvement of immunotherapy of breast cancer
by: Xi Cao, et al.
Published: (2022-10-01) -
The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
by: Camille Moeckel, et al.
Published: (2023-04-01) -
The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy
by: Anastasia Mpakali, et al.
Published: (2021-01-01)